{
    "organizations": [],
    "uuid": "1a72a938fa78e6a3b50fdf47a8acc84a2250c54b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cellect-announces-opening-of-secon/brief-cellect-announces-opening-of-second-clinical-trial-site-and-approval-from-safety-board-for-dose-escalation-idUSASB0C0ZO",
    "ord_in_thread": 0,
    "title": "BRIEF-Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 50 PM / Updated 8 minutes ago BRIEF-Cellect Announces beanpot northeastern Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation Reuters Staff 1 Min Read \nJan 16 (Reuters) - Cellect Biotechnology Ltd: \n* CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION \n* CELLECT BIOTECHNOLOGY - ‍SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO‘S ONGOING PHASE I/II STUDY​ \n* CELLECT BIOTECHNOLOGY -‍ GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-16T14:50:00.000+02:00",
    "crawled": "2018-01-16T15:02:24.024+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "beanpot", 
        "northeastern",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "opening",
        "second",
        "clinical",
        "trial",
        "site",
        "approval",
        "safety",
        "board",
        "dsmb",
        "dose",
        "escalation",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "cellect",
        "biotechnology",
        "ltd",
        "cellect",
        "announces",
        "opening",
        "second",
        "clinical",
        "trial",
        "site",
        "approval",
        "safety",
        "board",
        "dsmb",
        "dose",
        "escalation",
        "cellect",
        "biotechnology",
        "agreement",
        "hadassah",
        "medical",
        "center",
        "conduct",
        "clinical",
        "trial",
        "cancer",
        "patient",
        "co",
        "ongoing",
        "phase",
        "cellect",
        "biotechnology",
        "got",
        "approval",
        "dsmb",
        "escalate",
        "apograft",
        "fasl",
        "protein",
        "dosage",
        "enroll",
        "additional",
        "patient",
        "clinical",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}
